（ 研究業績 ） output

すべて 論文

  • 57. Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING.

    Endo R, Ueda T, Nagaoki T, Sato Y, Maishi N, Hida K, Harashima H*, Nakamura T*.
    Biomaterials 321: 123297 (2025).

    DOI : 10.1016/j.biomaterials.2025.123297.

    論文

  • 56. Targeting tumor endothelial cells by EGCG using specific liposome delivery system inhibits vascular inflammation and thrombosis.

    Jia Z, Maishi N, Takekawa H, Matsuda A, Nakade T, Nakamura T, Harashima H, Hida Y, Hida K*.
    Cancer Medicine 13: e70462 (2024).

    DOI : 10.1002/cam4.70462

    論文

  • 55. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.

    Endo R, Ueda T, Nagaoki T, Shima N, Sato Y, Harashima H*, Nakamura T*.
    J Control Release 372: 609-618 (2024).

    DOI : 10.1016/j.jconrel.2024.06.064

    論文

  • 54. Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells.

    Khalifa AM, Nakamura T*, Sato Y, Harashima H*.
    Exp Hematol Oncol 13: 36 (2024).

    DOI : 10.1186/s40164-024-00502-w

    論文

  • 53. Cancer immunotherapy with lipid nanoparticles loaded with a STING agonist against renal tumor lung metastasis.

    Nakamura T*, Sasaki S, Sato Y, Harashima H*.
    Pharmaceutics 16: 31 (2024).

    DOI : 10.3390/pharmaceutics16010031

    論文

  • 52. Harnessing Topology and Stereochemistry of Glycidylamine-Derived Lipid Nanoparticles for in vivo mRNA Delivery to Immune cells and their Application for Cancer Vaccination.

    Elwakil M, Suzuki R, Khalifa AM, Elshami RM, Isono T, Elewa Y, Sato Y, Nakamura T, Satoh T, Harashima H*.
    Adv Funct Mater 2303795 (2023).

    DOI : 10.1002/adfm.202303795

    論文

  • 51. Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles.

    Nakamura T*, Nakade T, Sato Y, Harashima H*.
    Int J Pharm 636: 122810 (2023).

    DOI : 10.1016/j.ijpharm.2023.122810

    論文

  • 50. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody.

    Khalifa AM, Nakamura T*, Sato Y, Sato T, Hyodo M, Hayakawa Y, Harashima H*.
    Int J Pharm 624: 122034 (2022).

    DOI : 10.1016/j.ijpharm.2022.122034.

    論文

  • 49. Retrograde axonal transport of liposomes from peripheral tissue to spinal cord and DRGs by optimized phospholipid and CTB modification.

    Fukui T, Tateno H, Nakamura T*, Yamada Y, Sato Y, Iwasaki N, Harashima H, Kadoya K*.
    Int J Mol Sci 23: 6661 (2022).

    DOI : org/10.3390/ijms23126661.

    論文

  • 48. Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.

    Maishi N, Sakurai Y, Hatakeyama H, Umemiya Y, Nakamura T, Endo R, Alam M, Li C, Annan, D, Kikuchi H, Morimoto H, Morimoto M, Akiyama K, Ohga N, Hida Y, Harashima H, Hida K*.
    Cancer Sci 113: 1855-1867 (2022).

    DOI : doi: 10.1111/cas.15323.

    論文